4BIO CAPITAL
4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences. They are focused on advanced therapies addressing high unmet medical and social needs. 4BIO Capital Partners is an emerging asset manager focusing on private equity and venture capital in high growth and high return segments of biotech - biologics, gene and cell therapy and bioinformatics.
4BIO CAPITAL
Industry:
Genetics
Founded:
2014-12-01
Status:
Active
Contact:
+44 (0) 203 427 5500
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail
Similar Organizations
Apollo Health Ventures
Apollo Health Ventures is a venture capital firm investing in seed and early stage biotechnology companies.
Batavia Biosciences
Batavia Biosciences focuses on accelerating the transition of biopharmaceutical product
Calimmune
Calimmune is a clinical-stage gene therapy company.
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-06-07 | Code Biotherapeutics | 4BIO Capital investment in Series A - Code Biotherapeutics | 75 M USD |
| 2022-06-06 | LUCA Science | 4BIO Capital investment in Series B - LUCA Science | 3.86 B JPY |
| 2022-01-04 | Ray Therapeutics | 4BIO Capital investment in Seed Round - Ray Therapeutics | 6 M USD |
| 2021-04-20 | Code Biotherapeutics | 4BIO Capital investment in Seed Round - Code Biotherapeutics | 10 M USD |
| 2021-03-01 | Carisma Therapeutics | 4BIO Capital investment in Series B - Carisma Therapeutics | 12 M USD |
| 2020-10-22 | Araris Biotech | 4BIO Capital investment in Seed Round - Araris Biotech | 15.2 M CHF |
| 2020-10-21 | SparingVision | 4BIO Capital investment in Venture Round - SparingVision | 44.5 M EUR |
| 2020-03-25 | Redpin Therapeutics | 4BIO Capital investment in Series A - Redpin Therapeutics | 15.5 M USD |
| 2018-01-01 | Autolus | 4BIO Capital investment in Post-IPO Equity - Autolus | N/A |
| 2017-12-20 | Orchard Therapeutics | 4BIO Capital investment in Series B - Orchard Therapeutics | 110 M USD |
More informations about "4BIO Capital"
4BIO Capital | Venture Investment | Greater London
4BIO Capital is a London-based venture capital firm focused solely on the advanced therapies sector. 4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical …See details»
Team | 4BIO Capital | London
4BIO Capital is a unique team of passionate academics, physician-scientists, industry executives and investment professionals that have come together to address the challenge of chronic …See details»
4BIO Capital - Crunchbase Investor Profile & Investments
4BIO Ventures is a London-based firm investing in venture capital and public equities in life sciences. They are focused on advanced therapies addressing high unmet medical and social needs. 4BIO Capital Partners is an emerging asset …See details»
4BIO Capital - Investments, Portfolio & Company Exits - Crunchbase
Jun 7, 2022 4BIO Capital 's most notable exits include Carisma Therapeutics, ADC Therapeutics, and Cellectis. Which industries has this organization had the most exits in? …See details»
4BIO Capital investment portfolio - PitchBook
4BIO Capital's latest investment was on 23-Oct-2024 in March Biosciences, a company within the Drug Discovery industry. Data Transparency. Meet our data hygiene team. Discover how our …See details»
4BIO Capital - LinkedIn
4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector. 4BIO’s objective is to invest in, support, and grow early stage companies developing ...See details»
4BIO Capital Strengthens Advisory Board and Investment Team
Mar 11, 2024 4BIO Capital +44 (0) 203 427 5500 [email protected] ICR Consilium Amber Fennell, Andrew Stern, Kris Lam +44 (0)20 3709 5700 [email protected]See details»
4BIO Capital Portfolio Company Code Biotherapeutics Closes …
Jun 7, 2022 Press Release 4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing 7 June 2022 London & Greater …See details»
4BIO Capital - Funding, Financials, Valuation & Investors
4BIO Capital . Connect to CRM . Save . Summary. Financials. Investments. People. Technology. Signals & News. Similar Companies. Highlights. Funds 1. Funding. 4BIO Capital has raised a …See details»
Strategy - 4BIO Capital | London
4BIO Capital is a trading name of 4BIO Partners LLP which is authorised and regulated by the Financial Conduct Authority (Reference Number 842764) 4BIO Partners LLP is an SEC …See details»
4BIO Capital leads oversubscribed $28.4 million Series A
Oct 23, 2024 4BIO Capital +44 (0) 203 427 5500 [email protected] ICR Consilium Amber Fennell, Kris Lam, Jonathan Edwards +44 (0)20 3709 5700 [email protected]See details»
4BIO Capital Portfolio Company Entact Bio Launches with $81 …
Dec 6, 2022 Press Release 4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement …See details»
4BIO Capital Portfolio Company Redpin Therapeutics to be …
Nov 16, 2022 London & New York – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies …See details»
Portfolio | 4BIO Capital | London
4BIO Capital is a trading name of 4BIO Partners LLP which is authorised and regulated by the Financial Conduct Authority (Reference Number 842764) 4BIO Partners LLP is an SEC …See details»
4BIO Capital Co-leads $10 Million Seed Financing in Code
4BIO Capital +44 (0) 203 427 5500 [email protected] AccessAlpha Worldwide LLC +1 (312) 585 6000 [email protected] Consilium Strategic CommunicationsSee details»
4BIO Capital Portfolio Company Trogenix Unveils Revolutionary …
LONDON, 18 November 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other ...See details»
News - 4BIO Capital | London
4BIO Capital is a trading name of 4BIO Partners LLP which is authorised and regulated by the Financial Conduct Authority (Reference Number 842764) 4BIO Partners LLP is an SEC …See details»
Trump Organization plans second Saudi Arabian tower in regional ...
3 hours ago The Trump Organization plans to build a Trump Tower in the Saudi capital Riyadh as part of a real estate expansion in the region including in the Emirati capital Abu Dhabi, Eric …See details»
4BIO Capital co-leads $30.3 million (¥3.86 Billion) - GlobeNewswire
Jun 6, 2022 4BIO Capital +44 (0)20 3427 5500 [email protected] Consilium Strategic Communications Amber Fennell, Allison Connolly, Genevieve Wilson +44 (0) 20 3709 5700See details»
4BIO Capital co-leads $30.3 million (¥3.86 Billion) oversubscribed ...
Jun 6, 2022 Press Release 4BIO Capital co-leads $30.3 million (¥3.86 Billion) oversubscribed Series B financing in LUCA Science Financing reflects the potential of mitochondrial therapy to …See details»